Please assess the completion status of the following clinical trial:

Trial Title: Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Liver biopsy acceptation~* B hepatitis grade over or equal to F2 Metavir score~* DNA HBV greater than 100000 copies/mL (or 10000 copies/mL if Ag Hbe negative)~* ALAT greater than 1.3 times the upper normal limit~Exclusion Criteria:~* HCV, HDV and HIV positive~* Pregnancy~* Decompensated liver cirrhosis~* Pretreated patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lamivudine alone
- 2 (Type: EXPERIMENTAL): Lamivudine + Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).